In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on GeoVax Labs (GOVX – Research Report), with a price target of $8.00. The company’s shares opened today at $0.58.
According to TipRanks, Bernardino is a 4-star analyst with an average return of 9.3% and a 27.05% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Cassava Sciences, Citius Pharmaceuticals, and Novavax.
GeoVax Labs has an analyst consensus of Moderate Buy, with a price target consensus of $7.00.
See Insiders’ Hot Stocks on TipRanks >>
Based on GeoVax Labs’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $5.93 million. In comparison, last year the company had a GAAP net loss of $2.24 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and cancer using its novel vaccine platform. It focuses on human immunodeficiency virus, zika virus, hemorrhagic fever viruses, and malaria. The company was founded by Harriet Latham Robinson and Donald G. Hildebrand on September 9, 2006 and is headquartered in Smyrna, GA.
Read More on GOVX:
- GeoVax to Present at the Emerging Growth Conference on September 6, 2023
- GeoVax Receives Notice of Allowance for Malaria Vaccine Patent
- GeoVax Labs receives notice of allowance from USPTO for malaria vaccine
- GeoVax announces first patients vaccinated in Phase 2 trial of GEO-CM04S1
- GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
